Autolus Therapeutics Valuation
| AUTL Stock | USD 1.40 0.02 1.45% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Autolus Therapeutics shows a prevailing Real Value of $3.28 per share. The current price of the firm is $1.4. Our model approximates the value of Autolus Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.61, shares outstanding of 266.14 M, and Operating Margin of (3.38) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Autolus Therapeutics' valuation include:
Price Book 1.3836 | Enterprise Value | Enterprise Value Ebitda 0.0326 | Price Sales 7.2876 | Enterprise Value Revenue 1.285 |
Undervalued
Today
Please note that Autolus Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Autolus Therapeutics is based on 3 months time horizon. Increasing Autolus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Autolus stock is determined by what a typical buyer is willing to pay for full or partial control of Autolus Therapeutics. Since Autolus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Autolus Stock. However, Autolus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.4 | Real 3.28 | Target 8.99 | Hype 1.65 |
The intrinsic value of Autolus Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Autolus Therapeutics' stock price.
Estimating the potential upside or downside of Autolus Therapeutics helps investors to forecast how Autolus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Autolus Therapeutics more accurately as focusing exclusively on Autolus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Autolus Therapeutics' intrinsic value based on its ongoing forecasts of Autolus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Autolus Therapeutics' closest peers.
Autolus Therapeutics Cash |
|
Autolus Therapeutics Total Value Analysis
Autolus Therapeutics is presently anticipated to have valuation of 65.7 M with market capitalization of 372.6 M, debt of 52.63 M, and cash on hands of 216.44 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Autolus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
65.7 M | 372.6 M | 52.63 M | 216.44 M |
Autolus Therapeutics Investor Information
About 72.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.38. Some equities with similar Price to Book (P/B) outperform the market in the long run. Autolus Therapeutics recorded a loss per share of 0.83. The entity had not issued any dividends in recent years. Based on the key indicators related to Autolus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Autolus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Autolus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Autolus Therapeutics has an asset utilization ratio of 1.29 percent. This suggests that the Company is making $0.0129 for each dollar of assets. An increasing asset utilization means that Autolus Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Autolus Therapeutics Profitability Analysis
Based on Autolus Therapeutics' profitability indicators, Autolus Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Autolus Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2016-09-30 | Previous Quarter -47.9 M | Current Value -79.1 M | Quarterly Volatility 20.7 M |
For Autolus Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Autolus Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Autolus Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Autolus Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Autolus Therapeutics over time as well as its relative position and ranking within its peers.
Autolus Therapeutics Earnings per Share Projection vs Actual
By analyzing Autolus Therapeutics' earnings estimates, investors can diagnose different trends across Autolus Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Autolus Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Autolus Therapeutics Ownership Allocation
Autolus Therapeutics holds a total of 266.14 Million outstanding shares. The majority of Autolus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Autolus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Autolus Therapeutics. Please pay attention to any change in the institutional holdings of Autolus Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Autolus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 10.12 M. Net Loss for the year was (220.66 M) with loss before overhead, payroll, taxes, and interest of (135.38 M).About Autolus Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Autolus Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Autolus Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Autolus Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Autolus Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Autolus Therapeutics. We calculate exposure to Autolus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Autolus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -117.8 M | -111.9 M | |
| Pretax Profit Margin | (24.90) | (26.15) | |
| Operating Profit Margin | (27.43) | (28.81) | |
| Net Loss | (25.08) | (26.33) | |
| Gross Profit Margin | (14.87) | (15.62) |
Autolus Therapeutics Current Valuation Indicators
Autolus Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Autolus Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Autolus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Autolus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Autolus Therapeutics' worth.When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.